Biopharmaceutical Services Provider Allucent Partners with THREAD to Address Modern Clinical Trial Needs of Small and Emerging Biotech Companies
CARY, N.C., June 20, 2023 – Global biopharmaceutical services provider Allucent announced on May 23, 2023 that it has partnered with THREAD, an innovative DCT and eCOA technology provider, to launch Allucent Patient Direct Trials. The new offering brings advanced technologies and development and regulatory expertise to small and emerging biotechnology companies to support them in designing and overseeing customized decentralized clinical trial approaches that address their needs.
Allucent will preferentially leverage THREAD’s decentralized clinical trial and eCOA technology across its global clinical trial portfolio. The announcement is part of a broader strategic initiative within Allucent to transform its clinical trial delivery to center on the patient to drive leading recruitment and retention outcomes, particularly for its rare disease and oncology programs. This expanded, three (3) year enterprise agreement will power Allucent’s new Patient Direct Trials offering for their customers.
Mark A. Goldberg, MD, chairman and chief executive officerof Allucent, stated, “THREAD has a track record of success as a leading provider of decentralized and eCOA technologies for our customers. Their no-code technology platform gives us the confidence we need to deliver high quality and on time studies for our customers.”
THREAD offers a configurable and flexible platform to operationalize a variety of study phases and designs across Allucent’s clinical trial portfolio. THREAD’s unique and tailored CRO enablement model translates THREAD’s expertise and embeds change management support to drive true trial modernization and patient first clinical research.
John Reites, co-founder and chief executive officer of THREAD stated, “Allucent’s Patient Direct Trials offering will enable their customers to center clinical trial delivery on the patient from study design to final analysis. We are excited to be selected as Allucent’s multi-year enterprise partner as their offering aligns with our mission of advancing research for everyone, everywhere.”
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of providers with proven expertise to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent’s individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients. Visit Allucent.com for more information.
THREAD’s® purpose is to leverage its decentralized research platform to enable studies for everyone, everywhere. The company’s uniquely combined clinical research technology and consulting services help biopharma and CROs to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, THREAD empowers studies to be accessible, efficient, and centered on the patient. Backed by health care investors Water Street Healthcare Partners and JLL Partners, THREAD is recognized as a leader by Everest Group’s Decentralized Clinical Trial Product PEAK Matrix® Assessment 2021/2022 and positioned in the Leader’s Category of the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology Solutions Vendor Assessment 2022. Visit THREADresearch.com to learn more.